Zabofloxacin
- Generic Name
- Zabofloxacin
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20FN5O4
- CAS Number
- 219680-11-2
- Unique Ingredient Identifier
- LV66BA6V2G
- Background
Zabofloxacin has been used in trials studying the treatment of Community Acquired Pneumonia and Chronic Obstructive Pulmonary Disease.
Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent
Phase 1
Recruiting
- Conditions
- Solid Tumor, AdultSolid TumorHepatocellular CarcinomaGastric CancerMetastatic Colorectal CancerAdvanced Solid Tumor
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Panolos Bioscience
- Target Recruit Count
- 30
- Registration Number
- NCT06075849
- Locations
- π°π·
CHA University Bundang Medical Center, Seongnam, Korea, Republic of
π°π·Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
π°π·The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of
Evaluation of Pharmacokinetics Profiles and Bactericidal Activity of Zabofloxacin
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-08-08
- Last Posted Date
- 2015-06-29
- Lead Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT02212795
- Locations
- π°π·
Chonbuk National University Hospital, Jeonju, Jeollabuk-do, Korea, Republic of
A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2012-08-06
- Last Posted Date
- 2014-10-13
- Lead Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
- Target Recruit Count
- 345
- Registration Number
- NCT01658020
- Locations
- π°π·
Asan Medical Center, Seoul, Korea, Republic of
Safety and Efficacy Study of Oral Zabofloxacin in Community Acquired Pneumonia
Phase 2
Terminated
- Conditions
- Community Acquired Pneumonia
- Interventions
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- IASO Pharma Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT01081964
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath